Alternatives to ranibizumab
1 same-class SPL records vs ranibizumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Lucentis
About ranibizumab
CIMERLI is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Used for: CIMERLI treats several eye conditions. These include wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV). These conditions can cause blurry vision or vision loss. CIMERLI helps to improve or stabilize your vision.
1 Anti-VEGF (Ophthalmic Injection) peers (wide set)
ranibizumab vs aflibercept · FAERS reaction fields
FAERS top-reaction field "Death" shows the widest count spread between ranibizumab and aflibercept in this extract (4,070-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | ranibizumab | aflibercept |
|---|---|---|
| Death | 3,783 | 7,853 |
| Visual Acuity Reduced | 2,888 | 1,244 |
| Visual Impairment | 1,623 | 2,013 |
| Cerebrovascular Accident | 1,235 | - |
| Eye Haemorrhage | 1,041 | 797 |
| Blindness | 1,036 | 1,459 |
| Vision Blurred | 1,029 | 1,161 |
| Eye Pain | 954 | 1,181 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
ranibizumab peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Anti-VEGF (Ophthalmic Injection): 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside ranibizumab? ▼
Reading a wide Anti-VEGF (Ophthalmic Injection) peer set (1 records)
ranibizumab (Lucentis) sits in a wide Anti-VEGF (Ophthalmic Injection) peer set (1 of 1 class peers shown). Labeled indication field for ranibizumab: CIMERLI treats several eye conditions.
Top FAERS reaction fields for ranibizumab total 15,105 reports across 10 reactions, set beside aflibercept. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for ranibizumab: see also the generic vs brand label guide when reading Lucentis SPL strings.
Read our methodology - how this data is sourced, computed, and verified.